P3 Health Partners' Q3 revenue down 5% due to payer rationalization

Reuters11-14

P3 Health Partners' Q3 revenue down 5% due to payer rationalization

Overview

P3 Health Q3 revenue falls 5% yr/yr due to network rationalization
Adjusted EBITDA loss for Q3 was $45.9 mln
Company aims for $120-$170 mln EBITDA expansion, targeting profitability by 2026

Outlook

P3 Health Partners expects 2025 revenue between $1.4 bln and $1.45 bln
Company anticipates 2025 medical margin of $67 mln to $82 mln
P3 projects 2025 adjusted EBITDA loss of $110 mln to $95 mln

Result Drivers

CARE ENABLEMENT MODEL - Expansion of Care Enablement Model drove positive momentum in core business, per CEO Aric Coffman
NETWORK RATIONALIZATION - Revenue decline attributed to intentional reduction in membership due to network and payer rationalization
STABLE MEDICAL COSTS - Medical cost trends remained stable, normalized for prior-year adjustments

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Total revenue		$345.3 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for P3 Health Partners Inc is $13.00, about 46.2% above its November 13 closing price of $7.00

Press Release: ID:nBw40lvbwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583548110?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 06:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583548110","market":"us","top_or_hot":-1,"title":"P3 Health Partners' Q3 revenue down 5% due to payer rationalization","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>P3 Health Partners' Q3 revenue down 5% due to payer rationalization</title></head><body><p><span>Overview</span></p><ul><li><p>P3 Health Q3 revenue falls 5% yr/yr due to network rationalization</p></li><li><p>Adjusted EBITDA loss for Q3 was $45.9 mln</p></li><li><p>Company aims for $120-$170 mln EBITDA expansion, targeting profitability by 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>P3 Health Partners expects 2025 revenue between $1.4 bln and $1.45 bln</p></li><li><p>Company anticipates 2025 medical margin of $67 mln to $82 mln</p></li><li><p>P3 projects 2025 adjusted EBITDA loss of $110 mln to $95 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CARE ENABLEMENT MODEL - Expansion of Care Enablement Model drove positive momentum in core business, per CEO Aric Coffman</p></li><li><p>NETWORK RATIONALIZATION - Revenue decline attributed to intentional reduction in membership due to network and payer rationalization</p></li><li><p>STABLE MEDICAL COSTS - Medical cost trends remained stable, normalized for prior-year adjustments</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Total revenue</p></td><td></td><td><p>$345.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for P3 Health Partners Inc is $13.00, about 46.2% above its November 13 closing price of $7.00</p></li></ul><p>Press Release: <span>ID:nBw40lvbwa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>P3 Health Partners' Q3 revenue down 5% due to payer rationalization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nP3 Health Partners' Q3 revenue down 5% due to payer rationalization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>P3 Health Partners' Q3 revenue down 5% due to payer rationalization</title></head><body><p><span>Overview</span></p><ul><li><p>P3 Health Q3 revenue falls 5% yr/yr due to network rationalization</p></li><li><p>Adjusted EBITDA loss for Q3 was $45.9 mln</p></li><li><p>Company aims for $120-$170 mln EBITDA expansion, targeting profitability by 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>P3 Health Partners expects 2025 revenue between $1.4 bln and $1.45 bln</p></li><li><p>Company anticipates 2025 medical margin of $67 mln to $82 mln</p></li><li><p>P3 projects 2025 adjusted EBITDA loss of $110 mln to $95 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CARE ENABLEMENT MODEL - Expansion of Care Enablement Model drove positive momentum in core business, per CEO Aric Coffman</p></li><li><p>NETWORK RATIONALIZATION - Revenue decline attributed to intentional reduction in membership due to network and payer rationalization</p></li><li><p>STABLE MEDICAL COSTS - Medical cost trends remained stable, normalized for prior-year adjustments</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Total revenue</p></td><td></td><td><p>$345.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for P3 Health Partners Inc is $13.00, about 46.2% above its November 13 closing price of $7.00</p></li></ul><p>Press Release: <span>ID:nBw40lvbwa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PIII","symbol_name":"3 Health Partners","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP1EL:1","article_id":"2583548110","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583548110","pubTimestamp":1763073752,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"P3 Health Partners' Q3 revenue down 5% due to payer rationalizationOverviewP3 Health Q3 revenue falls 5% yr/yr due to network rationalizationAdjusted EBITDA loss for Q3 was $45.9 mlnCompany aims for $","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PIII":"3 Health Partners","BK4196":"保健护理服务"},"translate_title":"由于付款人合理化，P3 Health Partners第三季度收入下降5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PIII":0.9},"content_text":"P3 Health Partners' Q3 revenue down 5% due to payer rationalizationOverviewP3 Health Q3 revenue falls 5% yr/yr due to network rationalizationAdjusted EBITDA loss for Q3 was $45.9 mlnCompany aims for $120-$170 mln EBITDA expansion, targeting profitability by 2026OutlookP3 Health Partners expects 2025 revenue between $1.4 bln and $1.45 blnCompany anticipates 2025 medical margin of $67 mln to $82 mlnP3 projects 2025 adjusted EBITDA loss of $110 mln to $95 mlnResult DriversCARE ENABLEMENT MODEL - Expansion of Care Enablement Model drove positive momentum in core business, per CEO Aric CoffmanNETWORK RATIONALIZATION - Revenue decline attributed to intentional reduction in membership due to network and payer rationalizationSTABLE MEDICAL COSTS - Medical cost trends remained stable, normalized for prior-year adjustmentsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Total revenue$345.3 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for P3 Health Partners Inc is $13.00, about 46.2% above its November 13 closing price of $7.00Press Release: ID:nBw40lvbwaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583548110","isCrawlerRequest":true}